m+Medelevator.RU
← Поиск публикаций
Fertility and sterility · 2025

To rescue or not to rescue immature oocytes: prospects and challenges.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Coticchio Giovanni, Cimadomo Danilo, De Vos Michel, Ebner Thomas, Esbert Marga, Escribá Maria Jose, Gilchrist Robert B, Rienzi Laura

Аннотация

In vitro maturation (IVM) of immature oocytes has been explored for research and clinical purposes since the dawn of assisted reproductive technologies. Oocyte maturation is a highly specific process, on the basis of complex mutual relationships between the germ and somatic cell compartments. The complexity of this relationship has made the quest for achieving oocyte maturation in vitro arduous. In its classical form, in which intact cumulus-enclosed oocytes are collected after very mild or no ovarian stimulation, oocyte IVM is nonexperimental and has been proposed as a more friendly treatment for patients with polycystic ovary or polycystic ovary syndrome. By contrast, rescue IVM (r-IVM), which is the maturation in vitro of immature oocytes collected in standard ovarian stimulation cycles, is an experimental procedure, proposed to mitigate the impact of low oocyte maturation rates in certain patients. Achieving effective r-IVM has turned out to be an even more daunting task because oocytes are cultured only after cumulus cell removal and, therefore, without the crucial somatic metabolic and regulative support. Immature oocyte arrested at the germinal vesicle or metaphase I stage require different management for their maturation in vitro and exhibit different developmental and chromosomal competence. Therefore, their possible use for treatment suggests a dedicated approach. Overall, r-IVM has limited clinical efficacy due to suboptimal maturation and developmental competence of immature oocytes. This raises a cost/benefit question: that is, the definition of appropriate clinical indications. Rescue IVM is probably irrelevant to treatment cycles in which the absolute number of mature oocytes is high. Conversely, specific poor prognosis cases, involving low maturation rates, low oocyte yield, and/or low oocyte quality, could benefit from the contribution of even a single embryo generated from an in vitro matured oocyte. Future progress in this field will depend on our ability to mimic in vitro the support provided by cumulus cells to oocyte nuclear and cytoplasmic maturation.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты